跳转至内容
Merck
CN
  • Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells.

Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells.

Cell death & disease (2021-02-10)
Haein An, Jin Sun Heo, Pyunggang Kim, Zenglin Lian, Siyoung Lee, Jinah Park, Eunji Hong, Kyoungwha Pang, Yuna Park, Akira Ooshima, Jihee Lee, Minjung Son, Hyeyeon Park, Zhaoyan Wu, Kyung-Soon Park, Seong-Jin Kim, Illju Bae, Kyung-Min Yang
摘要

Although tetraarsenic hexoxide is known to exert an anti-tumor effect by inducing apoptosis in various cancer cells, its effect on other forms of regulated cell death remains unclear. Here, we show that tetraarsenic hexoxide induces the pyroptotic cell death through activation of mitochondrial reactive oxygen species (ROS)-mediated caspase-3/gasdermin E (GSDME) pathway, thereby suppressing tumor growth and metastasis of triple-negative breast cancer (TNBC) cells. Interestingly, tetraarsenic hexoxide-treated TNBC cells exhibited specific pyroptotic characteristics, including cell swelling, balloon-like bubbling, and LDH releases through pore formation in the plasma membrane, eventually suppressing tumor formation and lung metastasis of TNBC cells. Mechanistically, tetraarsenic hexoxide markedly enhanced the production of mitochondrial ROS by inhibiting phosphorylation of mitochondrial STAT3, subsequently inducing caspase-3-dependent cleavage of GSDME, which consequently promoted pyroptotic cell death in TNBC cells. Collectively, our findings highlight tetraarsenic hexoxide-induced pyroptosis as a new therapeutic strategy that may inhibit cancer progression of TNBC cells.

材料
货号
品牌
产品描述

Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid
Sigma-Aldrich
四甲基罗丹明乙酯高氯酸盐, suitable for fluorescence, ≥90% (HPCE)
Sigma-Aldrich
N-Acetyl-Asp-Glu-Val-Asp-al, ≥95%, powder
Sigma-Aldrich
MISSION® esiRNA, targeting human DFNA5
Sigma-Aldrich
Amyloid Protein Non-Aβ Component, ≥80% (HPLC)